Recombinant zoster vaccine in patients with inflammatory rheumatic diseases: efficacy, long-term protection and safety under immunosuppression.
Patients with inflammatory rheumatic diseases (IRDs) have a substantially increased risk of herpes zoster (HZ), driven by underlying immune dysregulation and immunosuppressive therapy, particularly high-dose glucocorticoids, biologic disease-modifying antirheumatic drugs and Jan…